CelLBxHealth has completed an oversubscribed US$10.9 million fundraise

December 2025 — CelLBxHealth has completed an oversubscribed US$10.9 million fundraise comprising a placing, subscription and retail offer.

CelLBxHealth is a specialist diagnostics company. Its proprietary Parsortix® technology can capture and harvest very rare cells, including circulating tumor cells (CTCs), from a blood sample. Parsortix has received FDA clearance for clinical use to guide precision cancer care.

Our role in the transaction

Oaklins Cavendish, one of Oaklins’ member firms in the UK, advised and supported CelLBxHealth in its fundraise. The transaction was particularly challenging given the company’s previously disclosed funding runway into the first quarter of 2026, as well as the rapid onboarding of a new management team. The new team, led by Jan Groen and Peter Collins, was delighted by the level of support from existing holders alongside substantial interest from new investors. Notably, the company raised more than twice its market capitalization, with investor demand ultimately scaled back. The strength of participation reflects investor support for the company’s strategy, its new leadership and confidence in its core technology.

Service

Funding, debt advisory & ECM

Parties

“We were delighted to see strong support in the fundraise from both existing shareholders and non-holders. This heavily oversubscribed funding gives us the much-needed capital to pursue our revised business strategy as we focus on the substantial market opportunity for the Parsortix platform. It was a pleasure working with Oaklins Cavendish, whose support helped bring all sides of the business together to deliver a successful fundraise despite very challenging circumstances. We look forward to significant commercial progress in 2026 and beyond.”

Peter Collins

Interim CEO, CelLBxHealth

Talk to the deal team

Geoff Nash

Director

London, United Kingdom
Oaklins Cavendish

View profile Get in touch

Related deals

Katalyst Diagnostics has been acquired by Cruinn Diagnostics

Healthcare

Katalyst Diagnostics has been acquired by Cruinn Diagnostics

Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.

Learn more

Tandem has completed a voluntary public tender offer for the shares of Compagnia dei Caraibi

Food & Beverage

Tandem has completed a voluntary public tender offer for the shares of Compagnia dei Caraibi

Tandem S.r.l. has completed a voluntary public tender offer for 25.99% of the shares in Compagnia dei Caraibi S.p.A.

Learn more

ICOP has transferred its listing from Euronext Growth Milan to Euronext Milan

Construction & Engineering Services

ICOP has transferred its listing from Euronext Growth Milan to Euronext Milan

ICOP S.p.A. has transferred its listing from Euronext Growth Milan to Euronext Milan.

Learn more